Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients

Authors: Johannes Stratmann, Chao-Jie Wang, Sebastian Gnosa, Åsa Wallin, David Hinselwood, Xiao-Feng Sun, Hong Zhang

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Dicer is aberrantly expressed in several types of cancers. Applying real-time PCR, we detected the expression of Dicer mRNA in normal mucosa (n = 162), primary colorectal cancer (CRC) (n = 162) and liver metastasis (n = 37), and analysed the relationship between Dicer expression and clinicopathological features. We also correlated the expression of Dicer mRNA to the miRNA expression of miR-141, miR-200a, miR-200b, mir-200c and miR-429 in liver metastases.

Methods

RT-PCR and qPCR were used to analyse the Dicer expression in normal mucosa, primary tumour and liver metastasis by using the High Capacity cDNA Reverse Transcription Kit and TaqMan™® Gene Expression assays for Dicer and GAPDH. RT-PCR and qPCR were used to detect miRNA expression in liver metastases by utilizing TaqMan® MicroRNA Reverse Transcription Kit and TaqMan® miRNA Assays. Statistical analyses were performed with STATISTICA.

Results

Dicer expression in rectal cancer (3.146 ± 0.953) was higher than in colon cancer (2.703 ± 1.204, P = 0.018). Furthermore the Dicer expression was increased in primary tumours (3.146 ± 0.952) in comparison to that in normal mucosa from rectal cancer patients (2.816 ± 1.009, P = 0.034) but this is not evident in colon cancer patients. Dicer expression in liver metastases was decreased in comparison to that of either normal mucosa or primary tumour in both colon and rectal cancers (P < 0.05). Patients with a high Dicer expression in normal mucosa had a worse prognosis compared to those with a low Dicer expression, independently of gender, age, tumour site, stage and differentiation (P < 0.001, RR 3.682, 95% CI 1.749 - 7.750). In liver metastases, Dicer was positively related to miR-141 (R = 0.419, P = 0.015).

Conclusion

Dicer is up-regulated in the early development of rectal cancers. An increased expression of Dicer mRNA in normal mucosa from CRC patients is significantly related to poor survival independently of gender, age, tumour site, stage and differentiation.
Appendix
Available only for authorised users
Literature
1.
Gill S, Thomas RR, Goldberg RM: Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther. 2003, 18: 683-692. 10.1046/j.1365-2036.2003.01735.x.CrossRefPubMed
2.
Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 2003, 348: 919-932. 10.1056/NEJMra012242.CrossRefPubMed
3.
4.
von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP: The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007, 50: 839-855. 10.1007/s10350-006-0848-z.CrossRefPubMed
5.
6.
Mott JL: MicroRNAs Involved in Tumor Suppressor and Oncogene Pathways: Implications for Hepatobiliary Neoplasia. Hepatology. 2009, 50: 630-637. 10.1002/hep.23010.CrossRefPubMedPubMedCentral
7.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840.CrossRefPubMed
8.
Thiery JP, Acloque H, Huang RYJ, Nieto MA: Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 2009, 139: 871-890. 10.1016/j.cell.2009.11.007.CrossRefPubMed
9.
Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Grazia Daidone M, Bicciato S, Piccolo S: A MicroRNA Targeting Dicer for Metastasis Control. Cell. 2010, 141: 1195-1207. 10.1016/j.cell.2010.05.017.CrossRefPubMed
10.
11.
Takeshita D, Zenno S, Lee WC, Nagata K, Saigo K, Tanokura M: Homodimeric structure and double-stranded RNA cleavage activity of the C-terminal RNase III domain of human dicer. J Mol Biol. 2007, 374: 106-120. 10.1016/j.jmb.2007.08.069.CrossRefPubMed
12.
13.
Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, Dacic S: Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma. Cancer Res. 2007, 67: 2345-2350. 10.1158/0008-5472.CAN-06-3533.CrossRefPubMed
14.
Karube Y: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96: 111-115. 10.1111/j.1349-7006.2005.00015.x.CrossRefPubMed
15.
Grelier G, Voirin N, Ay A-S, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C: Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. BJC. 2009, 101: 673-683. 10.1038/sj.bjc.6605193.CrossRefPubMedPubMedCentral
16.
Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G: Down-regulation of dicer expression in ovarian cancer tissues. Clin Biochem. 2010, 43: 324-327. 10.1016/j.clinbiochem.2009.09.014.CrossRefPubMed
17.
Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ: Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008, 21: 676-684. 10.1038/modpathol.2008.33.CrossRefPubMed
18.
Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R: Up-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma. AJP. 2006, 169: 1812-1820.PubMedPubMedCentral
19.
Faber C, Horst D, Hlubek F, Kirchner T: Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer. 2011, 47: 1414-1419. 10.1016/j.ejca.2011.01.006.CrossRefPubMed
20.
Agostini M, Pucciarelli S, Calore F, Bedin C, Enzo M, Nitti D: miRNAs in colon and rectal cancer: A consensus for their true clinical value. Clin Chim Acta. 2010, 411: 1181-1186. 10.1016/j.cca.2010.05.002.CrossRefPubMed
21.
Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ: A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010, 465: 584-589. 10.1038/nature09092.CrossRefPubMedPubMedCentral
22.
Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J: Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights. 2006, 2: 113-121.PubMed
23.
Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009, 8: 102-10.1186/1476-4598-8-102.CrossRefPubMedPubMedCentral
24.
Wang CJ, Stratmann J, Zhou ZG, Sun XF: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and effect cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer. 2010, 10: 616-10.1186/1471-2407-10-616.CrossRefPubMedPubMedCentral
25.
26.
Kapiteijn E, Liefers GJ, Los LC, Klein Kranenbarg E, Hermans J, Tollenaar RAEM, Moriya Y, van de Velde CJH, van Krieken JHJM: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001, 195: 171-178. 10.1002/path.918.CrossRefPubMed
27.
Dimberg J, Samuelsson A, Hugander A, Soderkvist P: Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999, 45: 730-732. 10.1136/gut.45.5.730.CrossRefPubMedPubMedCentral
28.
Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, Costa A, Grazia Daidone M, Leo E, Pilotti S, Bertario L, Pierotti MA: Different Genetic Features Associated with Colon and Rectal Carcinogenesis. Clin Cancer Res. 2004, 10: 4015-4021. 10.1158/1078-0432.CCR-04-0031.CrossRefPubMed
29.
Chen LC, Hao CY, Chiu YSY, Wong P, Melnick JS, Brotman M, Moretto J, Mendes F, Smith AP, Bennington JA, Moore D, Lee NM: Alteration of gene expression in normal-appearing colon mucosa of APC min mice and human cancer patients. Cancer Res. 2004, 64: 3694-3700. 10.1158/0008-5472.CAN-03-3264.CrossRefPubMed
30.
Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9: 582-589. 10.1038/embor.2008.74.CrossRefPubMedPubMedCentral
Metadata
Title
Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients
Authors
Johannes Stratmann
Chao-Jie Wang
Sebastian Gnosa
Åsa Wallin
David Hinselwood
Xiao-Feng Sun
Hong Zhang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-345

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Literature survey on epidemiology and pathology of gangliocytic paraganglioma

Research article

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression

Research article

Quality of life assessment as a predictor of survival in non-small cell lung cancer

Research article

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas

Research article

Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer

Research article

Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits